Latent TB Infection-A Guide for Primary Health Care Providers

Latent TB Infection-A Guide for Primary Health Care Providers

Publication date: Nov 27, 2024

Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis (M. tuberculosis). Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease. It is estimated that up to 13 million people in the United States (U.S.) have LTBI. People with LTBI are infected with M. tuberculosis, but they do not have TB disease. People with LTBI do not have signs and symptoms of TB disease, and they cannot spread M. tuberculosis to others. While not everyone with LTBI will develop TB disease, about 5-10% of infected people will develop TB disease over their lifetimes if not treated for LTBI.

Progression from untreated LTBI to TB disease accounts for approximately 80% of U.S. TB cases. Identifying and treating people with LTBI is essential for controlling and eliminating TB disease in the U.S. LTBI treatment is effective for preventing TB disease. Primary care providers play a key role in achieving the goal of TB elimination because of their access to populations at high risk for TB. This guide is intended for primary care providers who care for individuals and populations who may be at risk for infection with M. tuberculosis. This document is not meant to be used as a substitute for CDC guidelines, but rather as a ready and useful reference. F

PDF

Concepts Keywords
3hp Blood
Breastfeeding Care
Leukemia Disease
Methadone Drug
Mycobacteriology High
Infected
Infection
Inh
Ltbi
Rif
Risk
Test
Treatment
Tst
Tuberculosis

Semantics

Type Source Name
disease MESH Infection
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease IDO bacteria
disease IDO role
disease MESH LATENT TUBERCULOSIS INFECTION
disease MESH AIDS
disease MESH Hepatitis
disease MESH Latent Infection
disease IDO blood
disease IDO immunodeficiency
disease IDO assay
drug DRUGBANK Isoniazid
disease MESH Morbidity
drug DRUGBANK Gold
drug DRUGBANK Rifampicin
drug DRUGBANK Rifapentine
disease MESH Infectious Diseases
drug DRUGBANK Ethanol
disease IDO history
drug DRUGBANK Prednisone
disease MESH silicosis
disease MESH chronic renal failure
disease MESH leukemia
disease MESH diabetes mellitus
disease MESH chest pain
disease MESH weight loss
disease IDO immunosuppression
drug DRUGBANK BCG vaccine
disease MESH hypersensitivity
drug DRUGBANK p-Phenylenediamine
disease MESH kidney disease
disease MESH cancer
disease MESH blister
pathway REACTOME Immune System
disease IDO drug susceptibility
drug DRUGBANK Rifamycin
disease MESH drug interactions
disease MESH HIV coinfection
pathway REACTOME Infectious disease
disease IDO infectious disease
disease IDO symptom
drug DRUGBANK Pyridoxine
drug DRUGBANK Methionine
disease MESH solitary pulmonary nodules
disease MESH liver disease
disease MESH Peripheral neuropathy
disease MESH alcoholism
pathway KEGG Alcoholism
disease MESH malnutrition
disease MESH hyperbilirubinemia
disease MESH hypotension
disease MESH anaphylaxis
disease MESH nephritis
disease MESH thrombocytopenia
disease MESH musculoskeletal pain
disease MESH petechiae
disease MESH anorexia
drug DRUGBANK Methadone
drug DRUGBANK Warfarin
drug DRUGBANK Haloperidol
drug DRUGBANK Diazepam
drug DRUGBANK Phenytoin
disease MESH Contraindication
drug DRUGBANK Maraviroc
drug DRUGBANK Rifabutin
disease MESH Opportunistic Infections
pathway REACTOME HIV Infection

Download Document

Leave a Comment

Your email address will not be published. Required fields are marked *